Etalanetug vs Moponetug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline

Etalanetug

Developed by Eisai

Phase 2/3 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT04971733 · Phase 1/2 · completed

The study treated 8 participants with etalanetug (E2814, Eisai's development code for this antibody) in open-label, single-arm cohorts without randomization, blinding or a comparator. Its primary endpoint was safety (treatment-emergent adverse events), not a controlled efficacy comparison, so it is weak evidence of efficacy.

Next expected readout: December 2026 · NCT06602258 (registry estimate)

Reported efficacy

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug up to 120 weeks); Number of Participants With Markedly Abnormal Laboratory Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Vital Signs Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings (From first dose of study drug up to 120 weeks); Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 Weeks (Pre-dose at Week 12): Safety: three participants had treatment-related adverse events at the 3000 mg dose, and 5 serious adverse events occurred in 3 participants. Target engagement: CSF MTBR-tau243 fell 50.6% after 12 weeks (n=7), with a maximum reduction of 71.6% at week 36 (n=4); CSF ptau217 fell 30.4% at 12 weeks (n=7). Eight participants enrolled; no control group. (not_applicable)

Result source: NCT04971733

Moponetug

Developed by Bristol-Myers Squibb under a licence from Prothena Biosciences Limited

Phase 2 in Alzheimer's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06268886 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEtalanetugMoponetug
CDR-SB, change—Trial running · NCT01760005—Not reported
ADAS-Cog11, change—Trial running · NCT01760005—Not reported
ADCS-ADL, change—Trial running · NCT01760005—Not reported
MMSE, change—Trial running · NCT01760005—Not reported
Amyloid PET, change (centiloids)—Trial running · NCT01760005—Not reported

CDR-SB, change

Etalanetug
—Trial running · NCT01760005
Moponetug
—Not reported

ADAS-Cog11, change

Etalanetug
—Trial running · NCT01760005
Moponetug
—Not reported

ADCS-ADL, change

Etalanetug
—Trial running · NCT01760005
Moponetug
—Not reported

MMSE, change

Etalanetug
—Trial running · NCT01760005
Moponetug
—Not reported

Amyloid PET, change (centiloids)

Etalanetug
—Trial running · NCT01760005
Moponetug
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Moponetug: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Etalanetug: 2 of 4 rows · Moponetug: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEtalanetug
Dropout rate
—4500 mga
NCT04971733 · Phase 1/2
show 2 more results
—1500 mg
NCT04971733 · Phase 1/2
—750 mg
NCT04971733 · Phase 1/2
Discontinued due to AEs
—4500 mga
NCT04971733 · Phase 1/2
show 2 more results
—1500 mg
NCT04971733 · Phase 1/2
—750 mg
NCT04971733 · Phase 1/2
Serious AEs
25%4500 mga
NCT04971733 · Phase 1/2
show 2 more results
0%1500 mg
NCT04971733 · Phase 1/2
0%750 mg
NCT04971733 · Phase 1/2
Most frequent reported AEs
4500 mga
upper respiratory tract infection 50%
agitation 25%
aphasia 25%
NCT04971733 · Phase 1/2
show 2 more results
1500 mg
bundle branch block left 14.3%
genital herpes 14.3%
agitation 0%
NCT04971733 · Phase 1/2
750 mg
covid-19 28.6%
chronic pigmented purpura 14.3%
diarrhoea 14.3%
NCT04971733 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etalanetug's landscape · Moponetug's landscape